Telix Pharmaceuticals (TLPPF) Long-Term Deferred Tax (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Long-Term Deferred Tax for 4 consecutive years, with $85.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $85.3 million in Q2 2026; TTM through Jun 2026 was $85.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $59.4 million, up 105.23% from the prior year.
• Long-Term Deferred Tax was $85.3 million for Q2 2026 at Telix Pharmaceuticals, up from $59.4 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $85.3 million in Q2 2026 and troughed at $13.3 million in Q4 2023.
• A 4-year average of $47.1 million and a median of $45.0 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax jumped 129.56% in 2024 and jumped 94.19% in 2025, its largest moves.
• Over 4 years, Long-Term Deferred Tax stood at $13.3 million in 2023, then jumped by 129.56% to $30.6 million in 2024, then surged by 94.19% to $59.4 million in 2025, then jumped by 43.71% to $85.3 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $85.3 million (Q2 2026), $59.4 million (Q4 2025), and $30.6 million (Q4 2024), per Business Quant data.